Concepedia

Fabienne Portales

FP

20

Publications

1.5K

Citations

17

H-Index

2009

Active since

Affiliations

Institut de Recherche en Cancérologie de Montpellier(Current)

Hôpital Beaujon

Sorbonne Université

Assistance Publique – Hôpitaux de Paris

Pitié-Salpêtrière Hospital

Fabienne Portales is an author at Institut de Recherche en Cancérologie de Montpellier specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

2009–2024

20

Publications

20

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Eric Van Cutsem, Margaret A. Tempero, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 404 citations · Full text

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 227 citations

, , +7

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Lilian Schwarz, Déwi Vernerey, Jean‐Baptiste Bachet et al. · BMC Cancer · 2018 · 114 citations · Full text

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

Pascal Hammel, Fabienne Portales, Laurent Mineur et al. · European Journal of Cancer · 2019 · 106 citations · Full text

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Eric Van Cutsem, R. Mayer, Stéphanie Laurent et al. · European Journal of Cancer · 2017 · 94 citations · Full text

Rows per page

1–5 of 20